Sucralfate diminishes basal acid output without affecting gastrin, H. pylori or gastritis in duodenal ulcer patients.
Twelve patients with active duodenal ulcer disease and Helicobacter pylori infection were treated with 1 g sucralfate q.d.s. for 1 month. Ulcers healed in 8 of the 12 patients without an alteration in the H. pylori-associated antral gastritis. Sucralfate produced a significant fall in basal acid output in all the patients, from a median of 4.8 (range 2.1-12.1) to 1.6 (0.4-8) mmol/h, P less than 0.01, whereas peak acid output was unchanged from 41 (21-59) before to 38 (24-55) mmol/h after treatment. Basal plasma gastrin concentrations and the meal-stimulated integrated gastrin response were not altered significantly by sucralfate: 8 (2-17) pmol/L and 732 (188-1045) pmol. min/L pre-treatment and 6 (2-17) pmol/L and 600 (140-1302) pmol. min/L post-treatment, respectively. The fall in basal acid output observed may contribute to prolonged duodenal ulcer remission after treatment with sucralfate.
Moss
S F
SF
Department of Gastroenterology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Thomas
D M
DM
Ayesu
K
K
Levi
S
S
Calam
J
J
D000328:Adult; D000368:Aged; D004381:Duodenal Ulcer / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005755:Gastrins / Q000097:blood*; D005756:Gastritis / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011706:Pyloric Antrum / Q000382:microbiology; D013392:Sucralfate / Q000494:pharmacology*
D005755:Gastrins; D013392:Sucralfate